Navigation Links
First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals' Lead Therapeutic Candidate for Treatment of Migraine, ALD403
Date:3/20/2013

to make a large impact in migraine. This preventative approach has been welcomed by patients, evidenced by the significant patient interest at all of our trial sites, and we are proud to advance ALD403 into a proof-of-concept trial while exploring additional applications for our core technologies with therapeutic candidates in other disease areas."

Research has shown that CGRP has a role as a trigger for migraine attacks, and inhibiting the peptide has demonstrated promise in preventing the onset of migraines. ALD403 is expected to be developed for patients experiencing multiple migraines per month with self-administered infrequent dosing.

Alder's core technology enables the production of antibodies in very high quantities via its Mab Xpress technology, allowing this class of therapeutics to enter disease areas that have previously been inaccessible for antibodies, such as migraine and cardiovascular disease. Proof of concept for this technology was achieved with clazakizumab, previously known as ALD518, a monoclonal antibody to the pro-inflammatory cytokine IL-6, which is currently under Phase 2 development by Bristol-Myers Squibb for autoimmune diseases (BMS-945429), while Alder is developing the antibody for cancer-related conditions.

About Alder Biopharmaceuticals

Alder Biopharmaceuticals Inc. uniquely identifies, develops and manufactures novel antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular and autoimmune and inflammatory disease areas. The company's second therapeutic program, an investigational monoclonal antibody for migraine, ALD403, inhibits a well-validated molecule shown to trigger migraine attacks, calcitonin gene-related peptide (CGRP), and is now in clinical trials. Clazakizumab, previously known as ALD518, is Alder's investigational monoclonal antibody to the pro-inflammatory cytokine IL-6. Alder is developing clazakizumab in Phase 2 clinical studies in m
'/>"/>

SOURCE Alder Biopharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
2. Wyckoff Heights Medical Center Is First New York Hospital to Offer Asthmapolis Mobile Asthma Management Program
3. Quest Diagnostics Launches Dementia Diagnostic Panel, First in Industry for Treatable Forms of Cognitive Impairment Based on Medical Guidelines
4. ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
5. Maddak Inc. Opens Possibilities For Disability Community With Launch Of Morph Wheels, First-Ever Foldable Wheelchair Wheels
6. N30 Pharmaceuticals Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
7. ISASS13 Shows Growth in New Exhibitors and First-Time Attendees
8. First Product in Tris Pharmas Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris
9. PDL BioPharma Provides First Quarter 2013 Royalty Revenue Guidance of $92 Million
10. UPDATE: Zimmer Announces 11% Increase in Quarterly Dividend for First Quarter of 2013
11. Zimmer Announces 11% Increase in Quarterly Dividend for First Quarter of 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)...  ResMed (NYSE: RMD ) today ... program, a comprehensive suite of software and service ... health care providers. ResMed Data ... information. It integrates valuable sleep and respiratory treatment ... platforms with customers, in-house or third-party electronic health ...
(Date:10/20/2014)... , Oct. 20, 2014   Taiho Oncology, ... Ltd. ( Japan ), announced that ... Fast Track designation for TAS-102 (nonproprietary names: trifluridine ... under investigation for the treatment of refractory metastatic ... initiated a rolling NDA submission to the FDA. ...
(Date:10/20/2014)... October 20, 2014 Norgine B.V. ... novel, low volume bowel preparation, NER1006, presented at the ... College of Gastroenterology (ACG), Philadelphia, PA ... stool weight and co-primary endpoint of cleansing success. The ... vs. MOVIPREP ® in screening colonoscopy patients. [1] ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2
... Calif., Oct. 13 In support of recent and ... unused, unwanted and expired medications, the medical professionals who ... today announced they will reduce the total cost of ... make treatment more widely available to those suffering from ...
... Oct. 13 Cardium Therapeutics (NYSE Amex: ... research findings that Excellagen, a topically applied formulated ... release of platelet-derived growth factor (PDGF) locally at ... shown to play an essential role in the ...
Cached Medicine Technology:Waismann Method Extends Aid in an Effort to Make Treatment More Widely Available 2Waismann Method Extends Aid in an Effort to Make Treatment More Widely Available 3Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process 2Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process 3Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process 4Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process 5Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process 6Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process 7
(Date:10/20/2014)... The Advocator Group, LLC is proud ... for Suicide Prevention’s (AFSP) Out of the Darkness walk ... that hosts hundreds of community walks throughout the country ... to help understand and prevent suicide through not only ... , The Advocator Group shares this passion for ...
(Date:10/20/2014)... 20, 2014 Women’s health specialist, Dr. ... & Gynecology of Columbus, Inc., A Division of MaternOhio ... to more than 100,000 patients annually. Dr. Murphy will ... and stages of a women’s life. She is accepting ... in Westerville and Dublin. , Dr. Murphy offers a ...
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
(Date:10/20/2014)... Los Angeles, CA (PRWEB) October 20, 2014 ... embodies fitness expertise, nutritional coaching, corporate wellness programming, authorship, ... MS, CPT, is excited to announce the release of ... , After many years of coaching thousands of ... pioneering nutrition tracking app that does not require calorie ...
(Date:10/20/2014)... 2014 Principle Business Enterprises, a family ... manufacturing top-of-the-line absorbent products. The company has recently ... popular brand, Tranquility® Premium Protection absorbent products. The ... gave its packaging a new look, and is currently ... to the public. , The new website, developed with ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2
... cord blood may be a more important factor associated with ... to allergens say researchers according to a new study . ... 1989 and 1990 who had a sample of their cord ... is an immune system response showing a sensitization to certain ...
... prevent bone loss may also help prevent prostate cancer from ... slow the spread of cancer to the bone and reduce ... to prevent bone loss. ,Estimates show prostate cancer spreads ... researchers recruited 311 men who were being given hormone therapy ...
... plays a major role in the development of a fetus. ... natural hormone can be toxic to a developing fetus. In ... // hormone and still be normal because of thyroid resistance. ... exposed to high thyroid hormone levels. ,Researchers studied extended ...
... tumor in the kidney appears to be a promising treatment, according ... a special needle into the tumor. A current is then passed ... or eliminate, it. The research finds patients not only respond to ... complications. ,For the past 50 years, the standard of care ...
... and help fight off diarrhea and pneumonia, researchers tested supplements ... with severe pneumonia// and they say that a simple ... . ,The study involved 270 children between ages 2 ... zinc per day while the other half received a placebo ...
... spinal or chest wall deformities face many serious health risks, ... a new lease on life. Prior to the experimental device, ... and the child would eventually end up with a chest ... specialists. ,The titanium rib is an expandable prosthesis that's ...
Cached Medicine News:
The True/Fix Cannulated Bone Screw System contains 7.0mm large cannulated bone screws and 3.5mm cortical and 4.0mm cannulated cancellous bone screws....
... Osteotomies and ligament surgery ... small number of hindfoot ... is the most common ... suitable staples allow very ...
The base of the staple is round and threaded to enable screwing onto the stapler. The base also has spikes. The legs of the staple are contoured to prevent the staple from backing out....
... Cement consists of a two ... bone cement liquid within a ... polyethylene bag,containing bone cement powder ... interiors of the blister pack,and ...
Medicine Products: